| 6.32 0.05 (0.8%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.76 | 1-year : | 15.23 |
| Resists | First : | 10.06 | Second : | 13.03 |
| Pivot price | 6.57  |
|||
| Supports | First : | 5.26 | Second : | 4.38 |
| MAs | MA(5) : | 6.01  |
MA(20) : | 7.1 |
| MA(100) : | 17.87 |
MA(250) : | 40.65 |
|
| MACD | MACD : | -1.5 |
Signal : | -1.6 |
| %K %D | K(14,3) : | 26.5 |
D(3) : | 20.5 |
| RSI | RSI(14): 36.1 |
|||
| 52-week | High : | 82.8 | Low : | 5.26 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ DNA ] has closed above bottom band by 41.9%. Bollinger Bands are 64.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.52 - 6.54 | 6.54 - 6.56 |
| Low: | 6.15 - 6.17 | 6.17 - 6.2 |
| Close: | 6.27 - 6.31 | 6.31 - 6.35 |
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Fri, 13 Sep 2024
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Short Interest Up 86.2% in August - MarketBeat
Fri, 13 Sep 2024
Is Ginkgo Bioworks Holdings, Inc. (DNA) A Good High Risk High Reward Growth Stock To Buy? - Insider Monkey
Wed, 11 Sep 2024
Ginkgo Bioworks Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference - Kilgore News Herald
Mon, 19 Aug 2024
Ginkgo Bioworks enacts reverse stock split, amends charter - Investing.com
Fri, 16 Aug 2024
The Price Is Right For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Even After Diving 27% - Simply Wall St
Sat, 10 Aug 2024
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Reported, And Analysts Assigned A US$1.11 Price Target - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 6.4 (%) |
| Held by Institutions | 63.8 (%) |
| Shares Short | 7,150 (K) |
| Shares Short P.Month | 3,090 (K) |
| EPS | -18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.03 |
| Profit Margin | 0 % |
| Operating Margin | -274.5 % |
| Return on Assets (ttm) | -22.3 % |
| Return on Equity (ttm) | -76.9 % |
| Qtrly Rev. Growth | -30.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 4.27 |
| EBITDA (p.s.) | -14.71 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -305 (M) |
| Levered Free Cash Flow | -167 (M) |
| PE Ratio | -0.36 |
| PEG Ratio | -0.1 |
| Price to Book value | 0.39 |
| Price to Sales | 1.47 |
| Price to Cash Flow | -0.9 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|